99mTc-maraciclatide Granted FDA Fast Track Designation for the Visualization of Inflammation in Interstitial Lung Disease

LONDON, Feb. 12, 2026 /PRNewswire/ -- Serac Healthcare Limited, a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation to 99mTc-maraciclatide as a diagnostic...

Read More